STOCK TITAN

Ocean Biomedical, Inc. - $OCEA STOCK NEWS

Welcome to our dedicated page for Ocean Biomedical news (Ticker: $OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical stock.

Ocean Biomedical, Inc. (symbol: OCEA) is a pioneering biopharmaceutical company focused on transforming basic research into groundbreaking clinical treatments. The company excels in partnering with inventor-scientists and premier research institutes to bridge the critical gap between laboratory discoveries and clinical applications. This unique approach aims to expedite the development of new medicines, ensuring that groundbreaking treatments reach the patients who need them most.

Ocean Biomedical is at the forefront of medical innovation, dedicating its resources to crucial areas of unmet medical needs. The company's operations span several key areas, including chronic hepatitis B and other serious diseases, where there is a significant demand for advanced therapeutic solutions.

In recent times, Ocean Biomedical has made notable strides in its projects and collaborations, enhancing its portfolio of potential treatments. For instance, the ongoing development of VRON-0200, in collaboration with Virion Therapeutics, showcases the company’s commitment to addressing chronic hepatitis B. Such initiatives not only enhance the company's market position but also underline its commitment to improving global health outcomes.

Financially, Ocean Biomedical has maintained a stable condition, driven by strategic partnerships and thoughtful financial planning. The company actively engages with investors and stakeholders through regular updates and transparent communication. For more information, the investor relations team can be reached at connect@oceanbiomedical.com.

Ocean Biomedical's significance in the biopharmaceutical industry cannot be overstated. By focusing on the translational process from research to clinical development, the company plays a vital role in the healthcare ecosystem. This holistic and patient-centric approach ensures that new medical discoveries are not just theoretical but are translated into viable treatments that can dramatically improve patient quality of life.

For more updates on Ocean Biomedical's latest news, projects, and collaborations, visit their official website at www.oceanbiomedical.com.

Rhea-AI Summary

Ocean Biomedical (NASDAQ: OCEA) congratulated its JV partner Virion Therapeutics on presenting successful Phase 1b data for VRON-0200, a novel immunotherapy aiming for an HBV functional cure, at EASL 2024 Congress.

The data showcased that VRON-0200, using glycoprotein D as a checkpoint modifier, is safe, well-tolerated, and immunogenic for chronic HBV patients after a single intramuscular injection. This treatment could stimulate T cell responses even in patients with little to no prior HBV immunity.

This development could support Virion's other pipeline programs, such as VRON-0300 for advanced tumors. The global chronic HBV treatment market is expected to reach $6.5 billion by 2032, reflecting the high demand for new treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Summary

Ocean Biomedical (NASDAQ: OCEA) announced on May 30, 2024, that it received a notice from Nasdaq regarding the late filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filings with the SEC. This delay follows previous issues with filing its 10-K for the year ended December 31, 2023.

Nasdaq has required Ocean Biomedical to submit a compliance plan by June 14, 2024, and to file the delinquent Form 10-Q by October 14, 2024. The notice has no immediate impact on the listing or trading of Ocean Biomedical's stock, but further delays could affect its Nasdaq listing. The company aims to file the overdue report as soon as possible.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
none
-
Rhea-AI Summary

On May 16, 2024, Ocean Biomedical (NASDAQ: OCEA) announced a new patent for malaria therapeutic antibody discoveries by Dr. Jonathan Kurtis. These antibodies aim to prevent malaria infection and treat severe cases by inducing parasite death via apoptosis during a critical stage of the malaria cycle. This patent adds to Ocean Biomedical's global portfolio, particularly important as malaria strains show resistance to current Artemisinin-based treatments. Ocean is optimizing vaccine and therapeutic antibody formulations before IND submission and clinical trials. Malaria remains a leading cause of death, particularly among children, with 627,000 fatalities in 2022. The new patent strengthens Ocean Biomedical's efforts to address this unmet medical need, leveraging partnerships with top research institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
Rhea-AI Summary
Ocean Biomedical, Inc. received a notice from Nasdaq regarding the late filing of its Annual Report on Form 10-K for the period ended December 31, 2023. The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) and must submit a plan to regain compliance by June 14, 2024, and file the delinquent Form 10-K by October 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.31%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. congratulates JV partner Virion Therapeutics, on presenting first-ever human data for novel checkpoint modifier immunotherapy for HBV functional cure at APASL 2024. The Phase 1 data of VRON-0200 showed safety and tolerability in HBV-infected patients. Virion's CEO, Dr. Andrew Luber, highlighted the potential of VRON-0200 and other pipeline programs, aiming to revolutionize immunotherapy for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) congratulates joint venture partner, Virion Therapeutics, LLC, for their abstract acceptance at APASL's 33rd Annual Meeting, presenting first-ever human data on HBV immunotherapy. The presentation will focus on safety data from ongoing Phase 1B clinical trial of VRON-0200, a novel checkpoint modifier T cell vaccine designed for HBV functional cure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
conferences clinical trial
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced new findings in the peer-reviewed journal Immunity detailing the role of CHI3L1 in the growth of triple negative breast cancer. The research demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from killing the tumor. Ocean's anti-CHI3L1 antibody shows potential in reversing this process and suppressing breast cancer tumor growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) received a notice from Nasdaq stating non-compliance with filing its quarterly report on Form 10-Q for the period ended September 30, 2023. The company is delayed in filing due to an interpretation of SEC accounting guidance for certain Forward Purchase Agreements. Ocean Biomedical has to submit a plan by January 22, 2024, to regain compliance and file the delinquent Form 10-Q by May 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced that its joint venture partner, Virion Therapeutics, presented compelling preclinical oncology data at SITC 2023, demonstrating complete tumor clearance and a 10-fold increase in T cell responses. Virion is also enrolling their Phase 1b clinical trial for chronic hepatitis B virus with VRON-0200, targeting a $6.5B+ market opportunity by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.36%
Tags
none
Rhea-AI Summary
Ocean Biomedical's joint venture partner, Virion Therapeutics, has dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy for chronic Hepatitis B virus (HBV) infection. VRON-0200, a first-in-class treatment, aims to enhance and broaden a patient's immune response to overcome immune exhaustion. Initial clinical data is expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags

FAQ

What does Ocean Biomedical, Inc. do?

Ocean Biomedical, Inc. is a biopharmaceutical company dedicated to bridging the gap between basic research and clinical development to bring new medicines to patients.

What is the stock symbol for Ocean Biomedical, Inc.?

The stock symbol for Ocean Biomedical, Inc. is OCEA.

What are some recent projects of Ocean Biomedical?

Ocean Biomedical is actively developing VRON-0200 for chronic hepatitis B in collaboration with Virion Therapeutics and several other innovative clinical treatments.

How does Ocean Biomedical maintain its financial health?

The company maintains financial stability through strategic partnerships, thorough financial planning, and transparent communication with investors.

Who are the key partners of Ocean Biomedical?

Ocean Biomedical collaborates with leading inventor-scientists, research institutes, and organizations like Virion Therapeutics.

How can investors contact Ocean Biomedical?

Investors can contact Ocean Biomedical through their investor relations team at connect@oceanbiomedical.com.

What diseases does Ocean Biomedical focus on?

Ocean Biomedical focuses on diseases with significant unmet needs, including chronic hepatitis B and other serious medical conditions.

Where can I find more information about Ocean Biomedical's projects?

More information about Ocean Biomedical's projects can be found on their official website at www.oceanbiomedical.com.

What is Ocean Biomedical's approach to clinical development?

Ocean Biomedical partners with leading scientists and research institutes to translate basic research into clinical treatments, aiming to deliver innovative medicines to patients.

Who is the Communications Director of Ocean Biomedical?

Kevin Kertscher serves as the Communications Director of Ocean Biomedical.

Ocean Biomedical, Inc.

Nasdaq:OCEA

OCEA Rankings

OCEA Stock Data

44.70M
3.73M
71.99%
13.29%
1.99%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
NEW YORK